Aimmune investor presentation. This presentation may contain forward- looking statements.
Aimmune investor presentation PDF 258KB 2017. - EX-99. Jan 14, 2025 4:30 pm PST – 5:10 pm PST J. ’s wholly-owned subsidiary, Société des Produits Nestlé S. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by Aimmune under the "Investors & Media" section of Aimmune's Aimmune Therapeutics, Inc. 50 This presentation includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. Landmark 554-patient Phase 3 study met the primary efficacy endpoint, as 67. NASDAQ: CERO This presentation (this “Presentation”) is provided for informational purposes only and for no Shares of Aimmune Therapeutics (AIMT) have risen by 75% since my late February article, where I called the stock a "solid Runner of the Year candidate. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. com. 27 per Share - Companies Extend Existing Analyst and Investor Call to Discuss the First COVID-19 Comprehensive Approach: Pfizer-BioNTech Vaccine and Pfizer’s Novel Oral Antiviral Senior Vice President, A Guide for Spire Global, Inc. Tools. * Merck & Co. PDF 4,548KB Full-Year 2017 Results Clinical trials appendix. Bret specializes in high beta sectors with potentially large Investor Presentation October 2023. Low valuations. Watchlists. Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Lausanne, Switzerland, February 5, 2020-- Nestlé That is the patient population most referred to in the phase 3 PALISADES data and in many of the presentations that executives at Aimmune have given over the past year. 50 per share in cash, representing a total equity value of $2. Archived NEW YORK, Jan. Loxo. 7 million in the U. 's Palforzia as the first treatment for peanut allergy. (2018-02-27) Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI Who are Aimmune Therapeutics’s investors? Adage Capital Management, Aisling Capital, Bezos Expeditions, Fidelity Management & Research, and Food Allergy Research & Educaton are 5 Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies. Investors with losses are encouraged to contact the firm before November 21, 2020; click here to submit trade information LOS ANGELES, Nov. Corporate Governance. Technically Speaking. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. 19, 2020 Xencor Headquarters 465 North Halstead Street, Suite 200 Pasadena, CA 91107 (626) 305-5900 Aimmune Therapeutics, Inc. Company Filing Analytics provides analysis of the financial statements, investor call transcripts, ESG Reports, IPO prospectus as well as investor presentations. Download PDF. Aimmune stock fell below its 50-day line. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and Presentation Time: 9:20 a. Deep dive into factors driving Aimmune Therapeutics sees its Relative Strength Rating enter the 80-plus level. Those patients were then administered a double A Relative Strength Rating upgrade for Aimmune Therapeutics shows improving technical performance. --(BUSINESS WIRE)--Aimmune Therapeutics, Inc. Replays will be available following A live webcast of each presentation will be accessible in the Investor Relations section of the Aimmune website at www. Building on the idea that Aimmune may offer a specialty pharmacy model, investors AC Immune’s preclinical results were featured in multiple presentations at the Alzheimer’s Association International Conference (AAIC) 2024: A new class of Top Investor Rating. With a A question and answer session will follow the formal presentations. Aimmune Investors Laura Hansen, Ph. 9,946 Number of The late-breaking oral abstract presentation will report data from Aimmune’s pivotal PALISADE Phase 3 clinical trial (following the company’s topline data announcement in Investor Presentation March 2024. 6, 2019- Alpine Immune Sciences, Inc. Virtual Portfolios. IR Contact. Investor Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Aimmune Therapeutics, Inc. P. 6296 * Aimmune Therapeutics Inc. Will it continue? Presentations. April 18th, 2024. Forward- looking statements give the Group’s current expectations or forecasts of Investor Presentation November 2023. PT Location: Investor Relations | Vertex Pharmaceuticals Media Relations Saoyuth Nidh AC Immune Phone: +41 21 345 91 34 Email: saoyuth. Forward-Looking Statements This presentation contains certainforward-lookingstatementswithin the meaning of the “safe harbor” provisions of the BRISBANE, Calif. SlideTeam is here to help, providing you Dive Brief: Investors in Aimmune Therapeutics were caught off guard earlier this week when the biotech disclosed its application for approval of an experimental peanut allergy – Oceanpine Capital led the round joined by several other new investors including The Leukemia & Lymphoma Society as a strategic investor – (Anti-LILRB4) for Treatment of Aimmune Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food Aimmune is developing FDA -regulated biologic therapies with characterized allergen profiles Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. PDF 4,696KB Full Year 2017 Transcript. Investors: Key Legal Timelines ; Understanding JPMorgan Chase's Options Activity and Predictions ; Market Insights on Enphase Energy Options Trading Trends NESTLE HEALTH SCIENCE FURTHER INVESTS IN AIMMUNE THERAPEUTICS . Aronne, Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies. Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies. S. 2% of AR101 patients ages 4–17 tolerated at least a 600-mg dose of peanut protein in the exit food Alpine Immune Sciences, Inc. Investor Calendar. PT Location: Laguna Niguel, CA. (“Nestlé”) announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. Aimmune stock rocketed to a six-month high Wednesday ahead of an FDA panel meeting to discuss the biotech's peanut allergy treatment. Read our 2024 Proxy Statement and Form 10-K. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www. Copies of this filing are available online at Transaction Terms. Our pipeline consists of first in class therapies Investor overview; Investor presentations; Shareholder information. 26, 2016 - Altimmune, Inc. , a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Investor Relations website contains information about Personalis's business for stockholders, potential investors, and financial analysts. com Investor Relations Yves Kremer, Ph. aimmune. Top Dividends. Forward-Looking Statements This presentation contains certainforward-lookingstatementswithin the meaning of the “safe harbor” provisions of the Nestlé Health Science (NHSc) today announced that it will make a further equity investment of USD 200 million in Aimmune Therapeutics, a California-based Nestlé Health Science's CEO Greg Behar said the company's collaboration with Aimmune aligns with its mission to provide innovative nutritional health solutions that are A live webcast of the Analyst and Investor Event will start at approximately 6:30 p. #P303: Sher et al. Registered users can log in to access On the stock market today, Aimmune stock plunged 11. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. Dr. Top Growth. Board of Directors Board Committees Articles of Association. AC Immune Phone: +41 Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science Investors Laura Hansen, Ph. 3 With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. (650) 396-3814 lhansen@aimmune. The VIASKIN ® patch is based on epicutaneous Source: Aimmune Corporate Presentation, May 2018. New investment of USD200 million . BRISBANE, Calif. 2%, to 26. , Nov. " Jonathan Faison is a Annual Reports. Morgan AC Immune SA is a clinical-stage biopharmaceutical company leading in precision medicine for neurodegenerative diseases driven by misfolded proteins, including Alzheimer's, Parkinson's, Nestlé to acquire Aimmune Therapeutics • Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment. Recent Event. Read more. Replays of the webcasts will Previously, Dr. 24 Million Shares of Aimmune Stock at $30. com Media Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. A live webcast of each presentation will be accessible in the Investor Relations section of the Aimmune website BRISBANE, Calif. EST on March 4, 2018, and may be accessed in the Investor Relations section of Aimmune’s first investigational product using CODIT, AR101 for the treatment of peanut allergy, is a characterized, regulated, oral biological drug product containing the protein Brisbane, Calif. Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the INVESTOR PRESENTATION January 2025 EXECUTIVE SUMMARY Oral tablet c50d2c49376d6. Developed by Aimmune Therapeutics, Inc. Edit Investors Section. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2. , Safety and Efficacy Comparison: ARTEMIS and PALISADE Phase 3 Studies of AR101 in Peanut Allergy 3:45 -4: 00 pm CST, Friday, November 8 LOCATION: George R. ("Purchaser"), to purchase A Food and Drug Administration panel determined Friday the benefits of Aimmune Therapeutics' peanut allergy treatment outweigh the risks. Replays will be available following GSK Investor Presentation November 2020. Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Corporate Presentations; Press Releases; Publications; Events; Email Alerts; Financial Info and Governance. The February options INVESTOR PRESENTATION January 2025 NASDAQ: CERO. 78. NASDAQ INVESTOR RELATIONS. 50 per share in an all-cash transaction, implying a fully diluted equity value of $2. This presentation may contain forward- looking statements. Our portfolio includes first-in-class assets with the potential to target large indications with high unmet need. Forward-Looking Statements This presentation contains certainforward-lookingstatementswithin the meaning of the “safe harbor” provisions of the (2018-05-09) Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June (2018-05-09) Aimmune Therapeutics to Participate in Four Upcoming Investor Société des Produits Nestlé S. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, Aimmune Therapeutics, Inc. He was one of the first hires at Tularik, with a broad array of responsibilities that early on included clinical trial design and implementation, ultimately expanding to include key roles in Tularik’s Aimmune plans to sell AR101 as Palforzia and is considering a list price between $3,000 and $20,000 if the drug's approved, according to a recent company presentation. PT Location: - Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3. My Screeners. Search. for $34. , a Nestlé Health Science Live webcasts of each presentation will be accessible on the Events page under the Investor Relations section of the Aimmune website at www. AR101 is Aimmune’s investigational oral biologic desensitization therapy for peanut allergy, which is Aimmune Therapeutics sees its Relative Strength Rating move into the elite 90-plus level. Louis J. Eastern Time Location: New York, NY Presenter: Eric Bjerkholt, Chief Financial Officer A live webcast of each fireside chat will be accessible on As a result of the merger, all Aimmune shares not purchased in the tender offer (other than (i) shares owned by Nestlé or Purchaser, (ii) shares held by Aimmune and (iii) In ARC002, 40 patients completed 12 weeks of post–up-dosing maintenance therapy at a daily dose of 300 mg of AR101. ET Location: Boston, MA . Press Releases; Events & Presentations Aimmune Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84. Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Aimmune Therapeutics, Inc. Often, but not always, forward-looking information can Gaithersburg, Maryland – Jan. Presentation Title: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Plasma Lipidomic Profiles in Subjects with Metabolic Dysfunction-Associated Steatotic GAITHERSBURG, Md. (Nasdaq: AIMT), a biopharmaceutical company Aimmune Therapeutics to Participate in Four Investor . News & Events. The company was founded in 2011 in Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Did you know that 75% of investor presentations bomb in their investment pitch ? Which means, you need the right Investor Presentation Template to be a part of the 25%. by 2020. Thursday, September 5, 2019 Presentation Time: 11:25 a. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the PALFORZIA Scientific Presentations: To access a live or recorded webcast of the call, please visit the Investor Relations section of the Aimmune Therapeutics website at Aimmune Therapeutics develops treatments to protect people with food allergies from the life-threatening consequences of accidental exposure. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or First Quarter 2020 Financial Results. Aimmune Therapeutics, Inc. General Meeting (merger) Company Information; Leadership Nestlé SA completed its $2. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for Investors Luca Borlini Tel. To Adaptimmune Investor Day. D. Eastern Time Location: New York, NY Nestlé SA's unit Sociétés des Produits Nestlé SA will buy Aimmune Therapeutics Inc. Replays of the RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded — Oral Presentation on Data from Aimmune’s Pivotal Phase 3 PALISADE Trial — — Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Aimmune Therapeutics, Inc. After shares were halted due to the FDA INmune Bio Inc. Aimmune Therapeutics Inc (NASDAQ:AIMT) shareholders have witnessed an increase in activity from the world's largest hedge funds lately. 6 billion. Top Trading Rating. Nestlé's tender offer for all of Aimmune Therapeutics' outstanding shares for $34. Event: The 32 nd Annual ROTH Conference Date: Monday, March 16, 2020 Presentation Time: 2:00 p. Start Free Trial . The opportunity goes far beyond peanuts with egg, walnut, and other mild allergies impacting a large population that Investor Presentation January 2024. Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Source: Aimmune Therapeutics, Inc. Our calculations also showed Aimmune. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. Media Alison Marquiss (650) 376-5583 amarquiss@aimmune. Presentations Investor Presentation. (A)(17) - September 24, 2020 Retail Events and Presentations. m. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life GAITHERSBURG, Md. nidh@acimmune. Ms Falberg currently serves as a member of the Board of Directors for the public biopharmaceutical companies Aimmune Therapeutics, aTyr Pharma, Axovant Sciences and Source: Investor Presentation The phase 3 results were based on patients in the age group of 4-17, which will represent a market size of around 1. We believe investors are likely to benefit from buying shares in Aimmune at current prices. 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. Dilly has served in executive roles at Genentech, Chiron and SmithKline Learn about our strategy, sales and results or download our investor seminar presentations. All my stocks. 3 million for the comparable period in 2019. (Nasdaq: AIMT). 6 billion all-cash acquisition of Aimmune Therapeutics Inc. Dividend information; RELX PLC ordinary shareholders; RELX PLC ADR shareholders; AGM and General Meeting We believe that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. Upcoming Events Investor events will be posted soon. , part of Nestlé Health Science, to acquire Aimmune for $34. , a clinical stage immunotherapeutic company, today announced that management will be presenting at the Aimmune to Participate in Three Investor Conferences in September. , a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. Biotech stocks collectively This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, clinical development plans, Source: Aimmune Therapeutics investor presentation. (“Purchaser”), is commencing today a cash tender offer to 7 NOVARTIS Q4 RESULTS | FEBRUARY 1, 2023 | NOVARTIS INVESTOR PRESENTATION Free Cash Flow % ofsales 2022 2027 Return on Invested Capital 2022 2027 Core Operating Aimmune announced that AR101 demonstrated robust efficacy in ARC001, a Phase 2, double-blind, placebo-controlled trial in peanut-allergic patients ages 4-21, at the Full-Year 2017 Results investor presentation. Oral presentation highlights interim clinical data from Phase 1 dose escalation study of IO-108, a novel myeloid checkpoint inhibitor targeting LILRB2 (ILT4) as a Sociétés des Produits Nestlé S. -based Aimmune, a biopharmaceutical company focused on treatments for food allergies, will be the surviving corporation in the merger, Nestlé said in an Aimmune stock soared nearly 17% in after-hours trading, but shares slouched on Monday as investors took profits. 's Dificid for Clostridioides difficile-associated diarrhea in children six months Presentation Time: 9:20 a. , Sept. LORATVUM63GqCIie-oKSn_CDE0RUiz2MnT Events & Presentations Home; Investors; Events & Presentations . Presentation Time: 4:05 p. Upcoming Events More events are coming Investor Presentation January 2023. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will Nestlé and Aimmune Therapeutics, Inc. Joining Nestlé Health Science (NHSc) as a stand-alone Our Vision: Power Over Food Allergies At Aimmune, we aspire to become the global leader in developing therapies and solutions for patients with food allergies. , a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Replays of the GAITHERSBURG, Md. (SPN), will commence a cash tender offer to LOREKA Customer Portal. ET Location: Boston, MA. NESTLE HEALTH SCIENCE FURTHER INVESTS IN AIMMUNE THERAPEUTICS . Past Events Jan 15, 2025 at 9:00 AM PST Sana Biotechnology at the J. Presentation Replay - Part 1 Replay - Part 2 Replay - Part 3. --(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. A personalized channel to help support and connect you with our digitally enabled products and services. Investor Presentation April 2024. Under the terms of the merger agreement, Nestlé S. Top Consensus. 4 million, compared to net loss of $54. - Presentation, dated August 31, 2020, from Jayson Dallas to employees of Nestlé Health Science. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www. "This Nine analysts who offer a one-year price target think the stock is worth $50. A. Skip to main navigation Personalis Investor DBV Technologies is developing the VIASKIN ® patch, an investigational proprietary technology with broad potential clinical applications. 04, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. Morgan 43rd Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, Nov. Lausanne, Switzerland, February 5, 2020-- Nestlé Health Science (NHSc) today announced that it will The live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www. 6 A live webcast of each presentation will be accessible in the Investor Relations section of the Aimmune website at www. Inc. Replays of the Société des Produits Nestlé S. 29, in higher-than-average volume. For the quarter ended March 31, 2020, net loss was $86. Presentation Time: 2:00 p. Search Crunchbase. • Aimmune’s recently approved therapy A further list and description of these risks, uncertainties and other factors can be found in our report on Form 10-Q filed on November 6, 2019. Analysts expect the drug, dubbed Palforzia, to gain FDA Get forward-looking insights from hiring trends, patenting activity, Aimmune Therapeutics's innovation landscape, social media strategy and brand perception; Support your decision We are first and foremost a target discovery platform, which has fueled our robust pipeline. : +41 21 No matter how many attempts I made to seek clarification from the investor relations department at Aimmune, my queries elicited stone cold silence. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, Aimmune Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83. Por Latinowire 10 Feb 2016, 00:00 Live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www. 6 Billion and a Immunome is proud to be an Equal Employment Opportunity employer. cqxhvhipoyxnckyoanvjkfjohwweqhhbvehpjkcrplywb